FBRXForte Biosciences, Inc.

argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte’s Friday closing price. The deal adds Forte’s experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, to Argenx’s immunology pipeline. Both companies’ boards have approved the deal, […]

argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how much optimism is already reflected in the price. argenx has returned 193.8% over the past five years, which puts extra focus on whether recent gains are backed by enduring fundamentals rather than just momentum. The tender offer to acquire Forte Biosciences may support growth expectations if integration goes well. At the same...

argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical research and development. Management attention on the proposed acquisition could influence argenx's capital allocation priorities. Investors are watching for details on valuation terms and integration plans once disclosed. This kind of transaction is one part of a broader opportunity set in biopharma and beyond, so it can be...

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited notable trading activity ahead of the deal, suggesting possible insider knowledge influencing price action. This case...

The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking. As leading pharmaceutical companies prepare for a $300 billion patent cliff in the second half of the decade, capital allocation has switched sharply toward restocking commercial pipelines with low-risk, high-conviction clinical assets. At the […]

argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer. The boards of both companies have approved the transaction, which is expected to close soon, subject to customary conditions. The deal will result in a change of control for Forte Biosciences, with all remaining shares acquired after completion of the tender. For existing and potential shareholders, Forte Biosciences, NasdaqCM:FBRX, now sits squarely in deal territory. The stock most...

argenx (ENXTBR:ARGX) is back in focus after agreeing to acquire Forte Biosciences in an all cash deal valued at about US$2.2b, centered on Forte’s anti CD122 antibody program FB102. See our latest analysis for argenx. argenx shares have had a strong run, with a 1 year total shareholder return of 54.32% and a 5 year total shareholder return of 202.61%. The 90 day share price return of 18.66% and the recent Forte deal suggest momentum has been building into recent earnings and pipeline...

The transaction is expected to close in the third quarter of 2026.

argenx stock has delivered a very strong 202.6% return over the past five years, yet its current valuation checks point to a more mixed picture rather than a clear bargain or clear overvaluation. With the share price around US$789.80 and expectations building around its immunology pipeline and recent deals, investors are weighing how much of that story is already reflected in the valuation. A 202.6% five year return shows argenx has already rewarded long term holders, which raises the bar...

Investor optimism was driven by AI optimism, a multibillion-dollar acquisition, and strong earnings execution.

Forte Biosciences stock soars on a $2.2 billion takeover proposal from Argenx. But is there any further upside left in FBRX shares? Let’s find out!

(Updates with index/price moves, macroeconomic data, and company/geopolitical news from the first pa

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte...

The benchmark US stock measures were pointing higher before the opening bell Monday after the US and

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

ArgenX’s acquisition of Forte Biosciences will add to its immunology portfolio, complementing existing autoimmune and neuromuscular disease therapies.

Forte Biosciences (FBRX) shares surged early Monday after the company agreed to be acquired by Belgi

Forte Biosciences (NASDAQ:FBRX) shares climbed 39. 2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an all-cash transaction valued at approximately $2.

Argenx NV ADR (NASDAQ:ARGX) has agreed to acquire Forte Biosciences Inc (NASDAQ:FBRX) in a transaction valued at approximately $2. 2 billion, expanding its portfolio of autoimmune disease treatments as it looks to build new growth opportunities beyond its flagship medicine, Vyvgart.

The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]